New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareRetatrutide vs DSIP

Retatrutide vs DSIP

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Retatrutide
Sleep OptimizationCognitive Enhancement
DSIP
Summary
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
DSIP is an endogenous neuropeptide originally isolated from rabbit cerebrospinal fluid that induces delta-wave (deep) sleep. It also modulates stress response, cortisol regulation, and LH secretion, making it valuable for sleep optimization and stress management.
Half-Life
~10–12 days
~30–60 minutes; however downstream sleep effects last 4–6 hours
Admin Route
SubQ
SubQ, IV, Intranasal
Research
Typical Dose
0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
100–400 mcg
Frequency
Once weekly
Once nightly
Key Benefits
  • ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
  • Superior to both semaglutide and tirzepatide in early trial comparisons
  • Triple receptor mechanism addresses multiple obesity pathways
  • Significant reduction in liver fat (MASH/NAFLD indication being studied)
  • Improved cardiovascular and metabolic markers
  • Once-weekly dosing
  • Potential for greatest weight loss of any currently investigated compound
  • Induces and deepens delta-wave (slow-wave) sleep
  • Reduces cortisol and normalizes HPA axis
  • Improves sleep quality in insomnia patients
  • Anti-stress and anxiolytic effects
  • May improve opiate/alcohol withdrawal symptoms
  • Analgesic properties through opioid modulation
  • Antioxidant and neuroprotective effects
Side Effects
  • Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
  • Diarrhea
  • Constipation
  • Heart rate increase (from glucagon receptor agonism)
  • +2 more
  • Generally well tolerated
  • Mild grogginess next morning at higher doses
  • Rare: hypotension
  • Potential for altered dream patterns
Stacks With